EMA says there may be a possible link between AstraZeneca vaccine and rare blood clots

The European Medicines Agency (EMA) said it has found a “possible link” between the AstraZeneca COVID-19 jab and “very rare cases” of blood clots. In a statement, EMA said that EMA’s safety committee (PRAC) has concluded today that unusual blood clots with low blood platelets should be listed as very rare side effects of Vaxzevria (formerly COVID-19 Vaccine AstraZeneca). 

In reaching its conclusion, the committee took into consideration all currently available evidence, including the advice from an ad hoc expert group. 

EMA is reminding healthcare professionals and people receiving the vaccine to remain aware of the possibility of very rare cases of blood clots combined with low levels of blood platelets occurring within 2 weeks of vaccination. So far, most of the cases reported have occurred in women under 60 years of age within 2 weeks of vaccination. Based on the currently available evidence, specific risk factors have not been confirmed. 

Photo Credit : https://commons.wikimedia.org/wiki/File:Oxford_AstraZeneca_COVID-19_vaccine_(2021)I(cropped).jpg